FIRZUNVY Trademark

Trademark Overview


On Tuesday, November 28, 2023, a trademark application was filed for FIRZUNVY with the United States Patent and Trademark Office. The USPTO has given the FIRZUNVY trademark a serial number of 98288740. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, November 22, 2024. This trademark is owned by Gilead Sciences Ireland UC. The FIRZUNVY trademark is filed in the Pharmaceutical Products category with the following description:

Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders

General Information


Serial Number98288740
Word MarkFIRZUNVY
Filing DateTuesday, November 28, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateFriday, November 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesAntiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 22, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGilead Sciences Ireland UC
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCarrigtohill, Co. Cork
IE

Trademark Events


Event DateEvent Description
Friday, December 1, 2023NEW APPLICATION ENTERED
Monday, January 22, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 26, 2024ASSIGNED TO EXAMINER
Thursday, June 27, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, June 27, 2024LETTER OF SUSPENSION E-MAILED
Thursday, June 27, 2024SUSPENSION LETTER WRITTEN
Friday, September 27, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, November 22, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 22, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 22, 2024ASSIGNED TO LIE